Class information for:
Level 1: ATAZANAVIR//RITONAVIR//LOPINAVIR

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
6181 1517 36.4 74%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
7 4 INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY 1353914
29 3       HIV//VIROLOGY//HIV 1 108954
773 2             EFAVIRENZ//NEVIRAPINE//RALTEGRAVIR 12242
6181 1                   ATAZANAVIR//RITONAVIR//LOPINAVIR 1517

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ATAZANAVIR authKW 962215 7% 45% 106
2 RITONAVIR authKW 905312 11% 28% 160
3 LOPINAVIR authKW 659598 6% 33% 98
4 SAQUINAVIR authKW 538469 6% 31% 85
5 FOSAMPRENAVIR authKW 282085 2% 48% 29
6 NELFINAVIR authKW 277935 4% 23% 59
7 PROTEASE INHIBITORS authKW 276820 14% 6% 219
8 AMPRENAVIR authKW 267258 2% 40% 33
9 TIPRANAVIR authKW 239053 2% 42% 28
10 INDINAVIR authKW 162757 3% 16% 50

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Infectious Diseases 28354 41% 0% 617
2 Pharmacology & Pharmacy 15647 59% 0% 890
3 Virology 7682 17% 0% 264
4 Immunology 2913 22% 0% 336
5 Microbiology 2595 18% 0% 277
6 Medical Laboratory Technology 818 4% 0% 62
7 Toxicology 571 7% 0% 99
8 Chemistry, Medicinal 18 2% 0% 28
9 Obstetrics & Gynecology 7 2% 0% 23
10 Medicine, General & Internal 3 3% 0% 39

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PK LTD 100635 0% 100% 5
2 CLIN PHARM 533 90569 0% 75% 6
3 ST STEPHENS 72771 2% 11% 32
4 PROGRAM HIV PREVENT TREATMENT IRD UMI 174 60381 0% 100% 3
5 SERGAS SERV GALEGA SAUDE 60381 0% 100% 3
6 INT AIDS THER Y EVALUAT 53670 0% 67% 4
7 STAT DATA ANAL 50362 2% 10% 24
8 HIV CLIN PHARMACOL PROGRAM 45284 0% 75% 3
9 MED HIV TREATMENT UNIT 45278 0% 38% 6
10 PROGRAM HIV PREVENT TREATMENT 42870 0% 30% 7

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANTIVIRAL THERAPY 60399 5% 4% 75
2 HIV CLINICAL TRIALS 56584 3% 7% 38
3 AIDS 31941 8% 1% 117
4 HIV MEDICINE 29440 3% 4% 40
5 THERAPEUTIC DRUG MONITORING 19334 4% 2% 60
6 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 18811 10% 1% 149
7 JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 15987 4% 1% 58
8 JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 7594 5% 1% 69
9 CLINICAL PHARMACOKINETICS 7146 2% 1% 29
10 CURRENT OPINION IN HIV AND AIDS 6177 1% 2% 16

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ATAZANAVIR 962215 7% 45% 106 Search ATAZANAVIR Search ATAZANAVIR
2 RITONAVIR 905312 11% 28% 160 Search RITONAVIR Search RITONAVIR
3 LOPINAVIR 659598 6% 33% 98 Search LOPINAVIR Search LOPINAVIR
4 SAQUINAVIR 538469 6% 31% 85 Search SAQUINAVIR Search SAQUINAVIR
5 FOSAMPRENAVIR 282085 2% 48% 29 Search FOSAMPRENAVIR Search FOSAMPRENAVIR
6 NELFINAVIR 277935 4% 23% 59 Search NELFINAVIR Search NELFINAVIR
7 PROTEASE INHIBITORS 276820 14% 6% 219 Search PROTEASE+INHIBITORS Search PROTEASE+INHIBITORS
8 AMPRENAVIR 267258 2% 40% 33 Search AMPRENAVIR Search AMPRENAVIR
9 TIPRANAVIR 239053 2% 42% 28 Search TIPRANAVIR Search TIPRANAVIR
10 INDINAVIR 162757 3% 16% 50 Search INDINAVIR Search INDINAVIR

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 JUSTESEN, US , (2008) PROTEASE INHIBITOR PLASMA CONCENTRATIONS IN HIV ANTIRETROVIRAL THERAPY.DANISH MEDICAL BULLETIN. VOL. 55. ISSUE 4. P. 165 -185 117 59% 8
2 PUNYAWUDHO, B , SINGKHAM, N , THAMMAJARUK, N , DALODOM, T , KERR, SJ , BURGER, DM , RUXRUNGTHAM, K , (2016) THERAPEUTIC DRUG MONITORING OF ANTIRETROVIRAL DRUGS IN HIV-INFECTED PATIENTS.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 9. ISSUE 12. P. 1583 -1595 74 56% 0
3 ASPIROZ, EL , BUELGA, DS , FIGUEROA, SC , GALERA, RML , PASCUET, ER , HURLE, ADG , SANCHEZ, MJG , (2011) POPULATION PHARMACOKINETICS OF LOPINAVIR/RITONAVIR (KALETRA) IN HIV-INFECTED PATIENTS.THERAPEUTIC DRUG MONITORING. VOL. 33. ISSUE 5. P. 573 -582 49 79% 7
4 WEISS, J , HAEFELI, WE , (2010) IMPACT OF ATP-BINDING CASSETTE TRANSPORTERS ON HUMAN IMMUNODEFICIENCY VIRUS THERAPY.INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 280. VOL. 280. ISSUE . P. 219-279 93 42% 13
5 LA PORTE, CJL , (2009) SAQUINAVIR, THE PIONEER ANTIRETROVIRAL PROTEASE INHIBITOR.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 5. ISSUE 10. P. 1313-1322 49 72% 11
6 MCCORMACK, SA , BEST, BM , (2014) PROTECTING THE FETUS AGAINST HIV INFECTION: A SYSTEMATIC REVIEW OF PLACENTAL TRANSFER OF ANTIRETROVIRALS.CLINICAL PHARMACOKINETICS. VOL. 53. ISSUE 11. P. 989 -1004 52 54% 8
7 BENTUE-FERRER, D , ARVIEUX, C , TRIBUT, O , RUFFAULT, A , BELLISSANT, E , (2009) CLINICAL PHARMACOLOGY, EFFICACY AND SAFETY OF ATAZANAVIR: A REVIEW.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 5. ISSUE 11. P. 1455-1468 50 65% 17
8 JANNEH, O , BRAY, PG , JONES, E , WYEN, C , CHIBA, P , BACK, DJ , KHOO, SH , (2010) CONCENTRATION-DEPENDENT EFFECTS AND INTRACELLULAR ACCUMULATION OF HIV PROTEASE INHIBITORS IN CULTURED CD4 T CELLS AND PRIMARY HUMAN LYMPHOCYTES.JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. VOL. 65. ISSUE 5. P. 906 -916 45 70% 4
9 ASPIROZ, EL , FIGUEROA, SEC , HURLE, ADG , SANCHEZ, MJG , (2013) NEW STRATEGIES IN THE OPTIMISATION OF LOPINAVIR/RITONAVIR DOSES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS.ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. VOL. 31. ISSUE 1. P. 36-43 46 60% 1
10 BUCKOREELALL, K , CRESSEY, TR , KING, JR , (2012) PHARMACOKINETIC OPTIMIZATION OF ANTIRETROVIRAL THERAPY IN PREGNANCY.CLINICAL PHARMACOKINETICS. VOL. 51. ISSUE 10. P. 639 -659 48 53% 14

Classes with closest relation at Level 1


Rank Class id link
1 11702 I TECH SERV//LAMIVUDINE//EMTRICITABINE
2 12516 EFAVIRENZ//NEVIRAPINE//CYP2B6
3 7021 RALTEGRAVIR//DOLUTEGRAVIR//ETRAVIRINE
4 2716 ANTIRETROVIRAL THERAPY//ROYAL FREE HIV MED//CD4 CELL COUNT
5 30421 NELFINAVIR//SAQUINAVIR NO//BECN1 PTDINS3K COMPLEX
6 545 HIV DRUG RESISTANCE//HIV 1 DRUG RESISTANCE//TRANSMITTED DRUG RESISTANCE
7 26650 NANOART//PHARMACEUT NANOMAT SCI//PHARMACOL EXPT NEUROSCI
8 18409 HUMAN PLACENTAL PERFUSION//MULTIDRUG RESISTANCE PHOSPHOGLYCOPROTEIN//PLACENTAL TRANSPORTERS
9 4819 PEDIATRIC HIV//EARLY INFANT DIAGNOSIS//EMPILWENI SERV UNIT
10 2183 HIV 1 PROTEASE//HIV PROTEASE//HIV 1 PROTEASE INHIBITORS

Go to start page